Tyrosine kinase inhibitorPhase 3 trialInvestigational
Pralsetinib
How it works
Blocks the growth signals that cancer cells receive from certain proteins, slowing their growth and spread.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, around 50% of patients achieved a reduction in tumor size, with a median progression-free survival of approximately 12 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Pralsetinib Study for Advanced Solid Tumors | Lung Cancer | preclinical | — | Source → |
| Combining pralsetinib and bevacizumab may improve lung cancer treatment | Lung Cancer | lab-study | — | Source → |
| Managing Side Effects of New Cancer Treatment | Lung Cancer | review | — | Source → |
| Pralsetinib Shows Promise in Treating Rare Lung Cancer | Lung Cancer | phase-1/2 | The overall response rate was 78% for treatment-naïve patients and 63% for prior platinum-based chemotherapy patients. | Source → |
| Re-challenging cancer drug pralsetinib after pneumonia in lung cancer patient | Lung Cancer | observational | — | Source → |
| Elderly Lung Cancer Patient Responds to Pralsetinib Treatment | Lung Cancer | observational | — | Source → |
| Pralsetinib Shows Promise in Treating Lung Cancer with RET Rearrangement | Lung Cancer | phase-2 | The response rate of the primary tumor was 74%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.